Benzodiazepine-induced anterograde amnesia: detrimental side effect to novel study tool.
Alzheimer’s disease
GABAA
anterograde amnesia
benzodiazepines
fear conditioning
sex differences
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
07
2023
accepted:
04
09
2023
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Benzodiazepines (BZDs) are anxiolytic drugs that act on GABAa receptors and are used to treat anxiety disorders. However, these drugs come with the detrimental side effect of anterograde amnesia, or the inability to form new memories. In this review we discuss, behavioral paradigms, sex differences and hormonal influences affecting BZD-induced amnesia, molecular manipulations, including the knockout of GABAa receptor subunits, and regional studies utilizing lesion and microinjection techniques targeted to the hippocampus and amygdala. Additionally, the relationship between BZD use and cognitive decline related to Alzheimer's disease is addressed, as there is a lack of consensus on whether these drugs are involved in inducing or accelerating pathological cognitive deficits. This review aims to inspire new research directions, as there is a gap in knowledge in understanding the cellular and molecular mechanisms behind BZD-induced amnesia. Understanding these mechanisms will allow for the development of alternative treatments and potentially allow BZDs to be used as a novel tool to study Alzheimer's disease.
Identifiants
pubmed: 37781704
doi: 10.3389/fphar.2023.1257030
pii: 1257030
pmc: PMC10536168
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1257030Subventions
Organisme : NIA NIH HHS
ID : R00 AG059953
Pays : United States
Informations de copyright
Copyright © 2023 Kaplan and Hunsberger.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
EXCLI J. 2020 Aug 03;19:1081-1099
pubmed: 33013265
PNAS Nexus. 2023 Apr 11;2(4):pgad065
pubmed: 37056471
Arch Gen Psychiatry. 2005 Feb;62(2):209-16
pubmed: 15699298
Learn Mem. 2020 Sep 15;27(10):423-428
pubmed: 32934095
Transl Psychiatry. 2021 Dec 3;11(1):612
pubmed: 34857741
Br J Anaesth. 2002 Oct;89(4):614-21
pubmed: 12393364
Eur J Neurosci. 2004 Oct;20(8):2214-24
pubmed: 15450101
Neuroscience. 2006;139(3):831-42
pubmed: 16542779
Trends Pharmacol Sci. 2018 Jul;39(7):659-671
pubmed: 29716746
Ochsner J. 2013 Summer;13(2):214-23
pubmed: 23789008
Nat Rev Neurosci. 2008 May;9(5):331-43
pubmed: 18382465
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):1-7
pubmed: 22326930
J Med Chem. 1979 Jan;22(1):1-7
pubmed: 34039
Trends Pharmacol Sci. 2018 Aug;39(8):710-732
pubmed: 29903580
Br J Pharmacol. 1972 Jan;44(1):140-4
pubmed: 5015033
Brain Res Mol Brain Res. 2000 Sep 15;80(2):153-65
pubmed: 11038248
Psychopharmacology (Berl). 1989;99(1):129-33
pubmed: 2506598
Life Sci. 1995;57(24):2215-22
pubmed: 7475974
Psychopharmacol Ser. 1988;6:218-29
pubmed: 2905807
Horm Behav. 1998 Oct;34(2):112-25
pubmed: 9799622
J Biol Chem. 2013 Jul 5;288(27):19343-57
pubmed: 23677991
Neurotoxicology. 2022 Sep;92:156-165
pubmed: 35940321
Learn Mem. 2005 Nov-Dec;12(6):573-8
pubmed: 16322359
Neurobiol Aging. 2019 Mar;75:11-24
pubmed: 30508732
Front Aging Neurosci. 2021 Nov 26;13:777404
pubmed: 34899279
Nat Commun. 2015 Apr 20;6:6872
pubmed: 25891999
Behav Brain Res. 2013 Mar 15;241:198-205
pubmed: 23261388
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3615-9
pubmed: 1565657
Health Psychol Res. 2021 Jun 11;9(1):24514
pubmed: 34746482
Pharmacol Rev. 2018 Oct;70(4):836-878
pubmed: 30275042
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:68-76
pubmed: 27208614
Drug Res (Stuttg). 2023 Jan;73(1):40-45
pubmed: 36302539
Mol Psychiatry. 2021 Feb;26(2):534-544
pubmed: 30504824
Nat Neurosci. 2015 Sep;18(9):1265-71
pubmed: 26280760
Neuroscience. 2013 Apr 16;236:345-72
pubmed: 23337532
J Neurosci. 2002 Jul 1;22(13):5572-80
pubmed: 12097508
Psychopharmacology (Berl). 2016 May;233(10):2005-13
pubmed: 26900079
Int J Geriatr Psychiatry. 2021 Jun;36(6):917-925
pubmed: 33382911
Brain Res. 1991 Dec 24;568(1-2):85-91
pubmed: 1814582
F1000Res. 2017 Feb 3;6:
pubmed: 28232865
Trends Pharmacol Sci. 2012 Nov;33(11):611-20
pubmed: 22981367
J Med Chem. 2000 Apr 20;43(8):1427-47
pubmed: 10780899
JAMA Psychiatry. 2015 Feb;72(2):136-42
pubmed: 25517224
Br J Pharmacol. 2005 Nov;146(6):817-25
pubmed: 16184188
J Psychopharmacol. 2012 Jun;26(6):845-56
pubmed: 21890586
Nature. 1999 Oct 21;401(6755):796-800
pubmed: 10548105
Hippocampus. 2015 May;25(5):545-55
pubmed: 25600672
Ann Intern Med. 1987 Aug;107(2):169-73
pubmed: 2886086
Nature. 2022 Apr;604(7904):190-194
pubmed: 35355020
Annu Rev Neurosci. 2001;24:897-931
pubmed: 11520922
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8980-5
pubmed: 12084936
Alzheimer Dis Assoc Disord. 2017 Oct-Dec;31(4):271-277
pubmed: 28582280
Life Sci. 1993;52(24):1935-45
pubmed: 8389411
Int J Geriatr Psychiatry. 2012 Dec;27(12):1248-57
pubmed: 22374884
Pharmacology. 1998 Jan;56(1):46-50
pubmed: 9467187
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7380-5
pubmed: 15870187
Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):113-7
pubmed: 26067923
Hum Psychopharmacol. 2021 May;36(3):e2774
pubmed: 33368617